Guided Therapeutics (GTHP) Retained Earnings (2010 - 2026)

Guided Therapeutics has disclosed Retained Earnings across 17 years of filings, most recently posting -$158.7 million for Q2 2026.

• In Q2 2026, Retained Earnings fell 2.37% year-over-year to -$158.7 million; the TTM figure through Jun 2026 stood at -$158.7 million (down 2.37% YoY), while the FY2025 annual figure was -$157.1 million, down 2.18% from the prior year.
• Retained Earnings came in at -$158.7 million for Q2 2026 at Guided Therapeutics, roughly flat from -$158.1 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$143.4 million in Q1 2022 to a low of -$158.7 million in Q2 2026.
• Average Retained Earnings over 5 years is -$151.7 million, with a median of -$151.9 million recorded in 2024.
• Year-over-year, Retained Earnings plunged 202.54% in 2022 and retreated 1.57% in 2024.
• Over 5 years, Retained Earnings stood at -$147.4 million in 2022, then slipped by 2.55% to -$151.1 million in 2023, then decreased by 1.71% to -$153.7 million in 2024, then decreased by 2.18% to -$157.1 million in 2025, then slipped by 1.05% to -$158.7 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$158.7 million in Q2 2026, -$158.1 million in Q1 2026, and -$157.1 million in Q4 2025.